Merck has signed a non-exclusive agreement with Bristol-Myers Squibb to carry out a Phase II trial evaluating combined investigational oral candidates MK-5172 and Daclatasvir to treat chronic Hepatitis C.
The investigational, orally available HCV NS3/4A protease inhibitor, MK-5172, is being evaluated in combination with other approved and investigational medications in the Phase II trials.
Go deeper with GlobalData
Merck Research Laboratories infectious diseases project leadership and management vice president Dr Eliav Barr said the potential of novel oral HCV regimens early in the development cycle can be evaluated through agreements that combine novel investigational candidates.
"We are pleased to collaborate with Bristol-Myers Squibb to advance this potential all-oral combination," Barr said.
The study is designed to assess the safety and efficacy profile of a once-daily oral combination regimen comprising Bristol-Myers’ investigational NS5A replication complex inhibitor, daclatasvir, and Merck’s investigational NS3/4A protease inhibitor, MK-5172.
Before the planned initiation of the Phase II trial, a Phase I safety evaluation of the investigational combination regimen is to be completed.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataUnder the deal, which does not cover clinical development activities beyond the Phase II study, Merck will conduct the Phase II trial.
Image: A Bristol-Myers Squibb R&D facility Princeton Rd, Princeton, New Jersey, US. Photo: Courtesy of Coolcaesar.
